-
公开(公告)号：US10174037B2
公开(公告)日：2019-01-08
申请号：US15576351
申请日：2016-05-31
发明人： Dong-Ming Shen , Michael P. Dwyer , Christopher J. Sinz , Deping Wang , Shawn J. Stachel , Daniel V. Paone , Ashley Forster , Richard Berger , Yili Chen , Yimin Qian , Shimin Xu , Chunmei Hu
摘要： The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
-
公开(公告)号：US10160762B2
公开(公告)日：2018-12-25
申请号：US15574411
申请日：2016-05-24
发明人： Dong-Ming Shen , Michael P. Dwyer , Christopher J. Sinz , Deping Wang , Shawn J. Stachel , Daniel V. Paone , Ashley Forster , Richard Berger , Yili Chen , Yimin Qian , Shimin Xu , Chunmei Hu , William D. Shipe , Jianmin Fu , Zhigang Guo , Haitang Li , Yingjian Bo
IPC分类号： C07D487/04 , A61K31/519 , A61P25/14 , A61P25/28 , A61P25/18 , A61P25/00 , A61P25/16
摘要： The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.
-
公开(公告)号：US20180148453A1
公开(公告)日：2018-05-31
申请号：US15576351
申请日：2016-05-31
发明人： Dong-Ming Shen , Michael P. Dwyer , Christopher J. Sinz , Deping Wang , Shawn J. Stachel , Daniel V. Paone , Ashley Forster , Richard Berger , Yili Chen , Yimin Qian , Shimin Xu , Chunmei Hu
摘要： The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
-
公开(公告)号：US20180134712A1
公开(公告)日：2018-05-17
申请号：US15574411
申请日：2016-05-24
申请人： Dong-Ming SHEN , Michael P. DWYER , Christopher J. SINZ , Deping WANG , Shawn J. STACHEL , Daniel V. PAONE , Ashley FORSTER , Richard BERGER , William D. SHIPE , Yili CHEN , Yimin QIAN , Shimin XU , Chunmei HU , Jianmin FU , Zhigang GUO , Haitang LI , Yingjian BO , Merck Sharp & Dohme Corp. , MSD R & D (China) Co., LTD.
发明人： Dong-Ming Shen , Michael P. Dwyer , Christopher J. Sinz , Deping Wang , Shawn J. Stachel , Daniel V. Paone , Ashley Forster , Richard Berger , Yilli Chen , Yimin Qian , Shimin Xu , Chunmel Hu , William D. Shipe , Jianmin Fu , Zhigang Guo , HAITANG LI , Yingjian Bo
CPC分类号： C07D487/04 , A61K31/519 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/28
摘要： The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.
-
公开(公告)号：US20170015633A1
公开(公告)日：2017-01-19
申请号：US15107233
申请日：2014-12-17
发明人： Dong Ming Shen , Melissa Egbertson , Richard Berger , XiaoXia Qian , Yimin Qian , Bart Harper , Meng Yang , Zack Zhi Qiang Guo , Vanessa L. Rada , Deping Wang , Timothy A. Cernak , Christopher Sinz , Ming Wang , Jonathan E. Wilson , Shimin Xu
IPC分类号： C07D239/36 , C07D401/12 , C07D403/04 , C07D403/06 , C07D487/04 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/04 , C07D417/04 , C07D401/06 , C07D403/12
CPC分类号： C07D239/36 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/04 , C07D417/04 , C07D487/04
摘要： Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.
摘要翻译： 公开了式（I）的嘧啶羧酰胺化合物，其可用作治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病，药物组合物及其用途的治疗剂。
-
公开(公告)号：US09815796B2
公开(公告)日：2017-11-14
申请号：US15107233
申请日：2014-12-17
发明人： Dong Ming Shen , Melissa Egbertson , Richard Berger , XiaoXia Qian , Yimin Qian , Bart Harper , Meng Yang , Zack Zhiqiang Guo , Vanessa L. Rada , Deping Wang , Timothy A. Cernak , Christopher Sinz , Ming Wang , Jonathan E. Wilson , Shimin Xu
IPC分类号： C07D239/36 , C07D401/12 , C07D401/06 , C07D403/04 , C07D403/14 , C07D487/04 , C07D405/12 , C07D405/14 , C07D413/04 , C07D417/04 , C07D403/12 , C07D403/06
CPC分类号： C07D239/36 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/04 , C07D417/04 , C07D487/04
摘要： Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.
-
公开(公告)号：US11066396B2
公开(公告)日：2021-07-20
申请号：US16309390
申请日：2017-06-19
发明人： Abbas Walji , Richard Berger , Craig A. Stump , Kelly-Ann S. Schlegel , James J. Mulhearn , Thomas J. Greshock , Deping Wang , Mark E. Fraley , Kristen G. Jones
IPC分类号： C07D413/04 , C07D413/10 , C07D413/14 , C07D413/12 , C07D417/14 , C07D471/04 , C07D471/14 , C07D487/04 , C07D491/048 , C07D491/052 , C07D271/06 , C07D498/04 , C07D513/04 , A61P25/28 , A61P29/00 , A61P35/00 , A61P25/18 , A61P11/06 , A61P3/10 , A61K45/06 , A61P9/00 , C07F7/08 , A61P37/00 , C07D271/113 , A61P37/02 , C07D417/12
摘要： The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.
-
公开(公告)号：US10351558B2
公开(公告)日：2019-07-16
申请号：US15550862
申请日：2016-02-12
申请人： Merck Sharp & Dohme Corp. , Dongfang Meng , Hong Li , Meng Yang , Manuel de Lera Ruiz , Sunita V. Dewnani , Tianying Jian , Dann L. Parker, Jr. , Ting Zhang , Louis-Charles Campeau , Harold B. Wood , Jiayi Xu , Richard Berger , Jane Yang Wu , Robert K. Orr , Shawn P. Walsh , Bart Harper
发明人： Dongfang Meng , Hong Li , Meng Yang , Manuel de Lera Ruiz , Sunita V. Dewnani , Tianying Jian , Dann L. Parker, Jr. , Ting Zhang , Louis-Charles Campeau , Harold B. Wood , Jiayi Xu , Richard Berger , Jane Yang Wu , Robert K. Orr , Shawn P. Walsh , Bart Harper
IPC分类号： C07D471/04 , C07D403/12 , C07D417/14 , A61P9/00 , C07D413/14 , C07D471/14 , C07D498/04 , C07D513/04
摘要： The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.
-
公开(公告)号：US20180162874A1
公开(公告)日：2018-06-14
申请号：US15579115
申请日：2016-06-20
申请人： Gregori J. MORRIELLO , Lehua CHANG , Ashley FORSTER , Yili CHEN , Michael P. DWYER , Richard BERGER , Ming WANG , Kausik K. NADA , Jaime L. BUNDA , William D. SHIPE , Merck Sharp & Dohme Corp.
发明人： Gregori J. Morriello , Michael P. Dwyer , Lehua Chang , Yili Chen , Ming Wang , Ashley Forster , Richard Berger , Kausik k Nanda , Jaime L Bunda , William D Shipe
IPC分类号： C07D498/04 , C07D473/34 , A61P25/18 , A61P25/16 , A61P25/28
CPC分类号： C07D498/04 , A61P25/06 , A61P25/16 , A61P25/18 , A61P25/28 , C07D473/34 , C07D487/04
摘要： The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
-
公开(公告)号：US20180022747A1
公开(公告)日：2018-01-25
申请号：US15550862
申请日：2016-02-12
申请人： Dongfang MENG , Hong LI , Meng YANG , Manuel de Lera RUIZ , Sunita V. DEWNANI , Tianying JIAN , Dann L. PARKER, JR. , Ting ZHANG , Louis-Charles CAMPEAU , Bart HARPER , Harold B. WOOD , Jiayi XU , Richard BERGER , Jane Yang WU , Robert K. ORR , Shawn P. WALSH , Merck Sharp & Dohme Corp.
发明人： Dongfang Meng , Hong Li , Meng Yang , Manuel de Lera Ruiz , Sunita V. Dewnani , Tianying Jian , Dann L. Parker, Jr. , Ting Zhang , Louis-Charles Campeau , Harold B. Wood , Jiayi Xu , Richard Berger , Jane Yang Wu , Robert K. Orr , Shawn P. Walsh , Bart Harper
IPC分类号： C07D471/04 , C07D403/12 , C07D498/04 , C07D417/14 , C07D513/04 , C07D471/14 , C07D413/14
CPC分类号： C07D471/04 , A61P9/00 , C07D403/12 , C07D413/14 , C07D417/14 , C07D471/14 , C07D498/04 , C07D513/04
摘要： The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.052 秒)
